Background: This is a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure Trial Registration No: NCT03521934 ( Link Sponsor: Sanofi Trial Status: Recruitment stopped Enrolling Centers: Worldwide: 384 centers Core Study Team Basel:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: July 2024
Kristin Shrestha Beate Hartmann Ph.D. Eleni Michou
Rebecca Meister Tania Coscia Maria Belkin